Pushing lower boundaries
GAITHERSBURG, Md.—Microdosing specialist Xceleron announced an agreement with Neurocrine Biosciences for a multi-arm Phase 0 study
GAITHERSBURG, Md.—Microdosing specialist Xceleron announced an agreement with Neurocrine Biosciences for a multi-arm Phase 0 study that will evaluate preliminary pharmacokinetics (PK) and metabolism of five compounds. Xceleron will conduct clinical trials in Europe with accelerator mass spectrometry analysis completed at the company's GLP accredited laboratories in York, U.K.